Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 16 for:    CFC1

Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability (ANI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02451761
Recruitment Status : Completed
First Posted : May 22, 2015
Last Update Posted : March 23, 2017
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

Apparently balanced chromosomal rearrangement (ABCR) associated with an abnormal phenotype is a rare but problematic event. It occurs in 6% of de novo reciprocal translocations and 9% of de novo inversions. Abnormal phenotype, including intellectual disability and / or multiple congenital anomalies (ID/MCA) may be explained either by associated cryptic genomic imbalances detectable by array-CGH or by gene disruption at the breakpoint. However, breakpoint cloning using conventional methods (i.e., fluorescent in situ hybridization (FISH), Southern blot) is often laborious and time consuming and cannot be performed routinely. Without complete investigation of these rearrangements, genetic counseling is a real challenge. Recently, the investigators and others showed that Next-Generation Sequencing (NGS) is a powerful and rapid technique to characterize ABCR breakpoints at the molecular level.

The ANI project (ABCR NGS ID) aims at characterizing at the molecular level ABCR in 55 patients presenting with intellectual disability and/or multiple congenital anomalies (ID/MCA) using NGS. The investigators make the hypothesis that ABCR account for the patient phenotype, either by gene disruption or position effect, since genomic imbalance would have been previously excluded by array-Comparative Genomic Hybridization (CGH).

The ANI project is a 3-year-long study that will be conducted by a consortium of 21 partners, including 19 french hospital cytogenetics laboratories, a research team (TIGER), and a cellular biotechnology center. Patients will be recruited by each Cytogenetics laboratory. ABCR breakpoints will be molecularly characterized by NGS and a first bio-informatics analysis. The results will be verified by amplification of junction fragments by polymerase Chain Reaction (PCR) followed by Sanger sequencing, allowing the localization of breakpoints at the base-pair level. In some complex cases, FISH experiment will be necessary to clarify the results. A second bio-informatics analysis will then determine breakpoints' characteristics (sequence, repeated elements, gene and regulatory elements). Finally, for each breakpoint, gene expression studies will be performed including the gene disrupted by the breakpoint and two neighboring genes. All these data, together with those already available in the literature and databases will be integrated to determine if the gene could account for the patient's phenotype, allowing an appropriate genetic counseling.

This project will identify new candidate genes involved in ID and developmental anomalies. It will also contribute to the development and evaluation of NGS as a diagnostic tool for ABCR and ID/MCA. It will also allow unraveling mechanisms and functional consequences of ABCR, in particular in term of position effect.

In conclusion, the ANI project will contribute to the improvement of diagnostic management and genetic counseling of patients with ID/MCA and ABCR. It will also contribute to the understanding of ABCR physiopathology and to the unraveling of pathway involved in development and brain function, thus improving genetic counseling for ID/MCA patients in general.


Condition or disease Intervention/treatment
Intellectual Disability Congenital Abnormalities Biological: Blood sampling

Layout table for study information
Study Type : Observational
Actual Enrollment : 55 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Molecular Characterization of Apparently Balanced Chromosomal Rearrangements by Next-generation Sequencing in 55 Patients With Intellectual Disability and/or Multiple Congenital Anomalies
Study Start Date : April 2015
Actual Primary Completion Date : February 2017
Actual Study Completion Date : February 2017


Group/Cohort Intervention/treatment
Sequencing
Blood sampling will be carried out in all patients ; molecular analysis and sequencing will be performed on these samples
Biological: Blood sampling



Primary Outcome Measures :
  1. Identification of candidate genes and genes responsible for the phenotype disrupted at the breakpoints [ Time Frame: At the end of the study (36 months) ]
    Blood samples will be collected at inclusion ; analysis wil be performed at the end of the study (between 30 and 36 months)


Secondary Outcome Measures :
  1. Development of a routine bio-informatic protocol for analysis of ABCR by NGS [ Time Frame: At the end of the study (36 months) ]
    Ratio between the number of breakpoints detected by both karyotype ans NGS and the number of breakpoints detected by karyotype alone.

  2. Number of patients presenting at least one disrupted gene [ Time Frame: At the end of the study (36 months) ]
    This outcome will help us ti confirm the NGS performance for the detection of breakpoints of ABCR.

  3. Number of patients for which a diagnosis could be performed [ Time Frame: At the end of the study (36 months) ]
    Number of patients for which a diagnosis could be performed (responsible gene) compared to the total number of patients. This ration will be compared to a reference raio of 10% by a unilateral test. This will allow us to evaluate a next-generation sequencing strategy in clinical context (diagnostic yield)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients presenting intellectual disability and/or multiple congenital anomalies
Criteria

Inclusion Criteria:

  • Abnormal phenotype: intellectual disability and/or multiple congenital anomalies.
  • Post-natal cases
  • ABCR diagnosed by standard karyotype, including reciprocal translocation, inversion, insertion and Complex Chromosomal Rearrangement (CCR).
  • de novo ABCR. Inherited ABCR could be included if the transmitting parent shows also an abnormal phenotype or if the rearrangement involves an imprinted chromosome.
  • Array-CGH results normal that mean absence of pathogenic imbalances. Identification of Variant Of Unknown Significance (VOUS) does not prevent from inclusion.
  • Information and written consent of patient or his legal representative (information and consent form available on request).
  • Covered by a Health System

Exclusion Criteria:

  • Pathogenic genomic imbalance demonstrated by array-CGH.
  • Identification of an independent etiology (i.e. monogenic disease, environment,…).
  • Rejection to participate ton the study
  • Weight inferior to 6 kg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02451761


Locations
Layout table for location information
France
laboratoire de Cytogénétique Constitutionnelle - Centre de Biologie et Pathologie Est
Bron, France, 69677
Sponsors and Collaborators
Hospices Civils de Lyon

Additional Information:
Layout table for additonal information
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT02451761     History of Changes
Other Study ID Numbers: 2014.858
First Posted: May 22, 2015    Key Record Dates
Last Update Posted: March 23, 2017
Last Verified: August 2016
Keywords provided by Hospices Civils de Lyon:
chromosomal rearrangement
next generation sequencing
intellectual disability
multiple congenital anomalies
gene disruption
Additional relevant MeSH terms:
Layout table for MeSH terms
Intellectual Disability
Congenital Abnormalities
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Neurodevelopmental Disorders
Mental Disorders